American Capital Agency Corp (AGNC)
Over the past week American Capital Agency’s price dwindled down to record lows and three insiders took this opportunity to buy back into the company’s stock.
Senior VP Christopher Kuehl purchased the smallest amount, adding 2,000 shares to his stake at $21.56 per share. This cost the VP a total of $43,120 for the transaction. Since his buy the price per share has increased approximately 1.02%. Kuehl now holds on to a total of 120,928 shares of company stock.
Senior VP and Chief Risk Officer Peter Frederico added 2,500 shares to his holdings this past week at an average price of $21.71 per share. The total transaction amount for this buy was $54,275. Since his buy the price per share has gone up about 0.32%. Frederico now holds on to at least 122,804 shares of company stock.
President and CIO Gary Kain made the largest buy on Oct. 30. The president purchased an additional 25,000 shares of his company’s stock at an average price of $21.66 per share. This buy cost him a total of $541,500. Since his buy, the price per share has increased approximately 0.61%.
These insiders took the opportunity to buy as the company’s price is currently trading at its lowest price since 2009.
American Capital Agency is a REIT that invests exclusively in residential mortgage pass-through securities and collateralized mortgage obligations on a leveraged basis. These investments consist of securities for which principal and interest are guaranteed by government-sponsored entities such as Fannie Mae and Freddie Mac.
American Capital Agency’s historical revenue and net income:
The company recently reported its third quarter financials which reported:
· Comprehensive income of $179 million, or $0.45 per share.
· Economic return for the period was a gain of $0.56 per common share.
· 2.2% economic gain on common equity for the quarter, or 8.7% annualized.
· Released a dividend of $0.80 per common share.
· Holds a $77.8 billion investment portfolio.
Over the past quarter the company also announced that it made open market purchases of 11.9 million of their common stock, or 3% of American Capital’s shares outstanding for $22.16 per share. This transaction cost the company $263 million. Since the buyback program was initiated, the company has purchased about 14.8 million shares for a total cost of approximately $347 million
The analysis on American Capital Agency reports that the company has issued $67.2 billion of debt over the past three year, they have issued $10.4 billion worth of new shares over the past three years and the company has had an operating loss over the past few years.
American Capital Agency has a market cap of $8.62 billion. Its shares are currently trading at around $21.73 with a P/E ratio of 3.70, a P/S ratio of 2.50 and a P/B ratio of 0.20. The company also currently holds a dividend yield of 20%.
Washington REIT (WRE)
Over the past week two directors at Washington REIT made notable buys back into the company.
On October 29 Director Charles Nason purchased 5,000 shares of Washington stock. He purchased these shares at an average price of $26.31 per share. This cost the director a total of $131,550. Since his buy, the price per share has dropped a minor -0.04%%. Nason now holds on to at least 40,073 shares of company stock.
On October 30 Director William Byrnes made a noticeably larger buy of 18,000 shares of company stock. The director purchased these shares at an average price of $26.19 per share for a total transaction amount of $471,420. Since his buy the price per share has increased a slight 0.42%. Byrnes now holds on to at least 26,154 shares of Washington REIT stock.
These buys come as the company’s price is rebounding from its 52-week low.
Washington REIT is a self-administered, self-managed, equity REIT investing in income-producing properties in the greater Washington metro region. The company owns a diversified portfolio of 70 properties totaling 8 million square feet of commercial space as well as 2,675 residential units.
Washington REIT’s historical revenue and net income:
Over the past quarter Washington REIT declared its 208th consecutive quarterly dividend. The dividend was declared on Oct. 23 and is payable on Dec. 31 to shareholders of the record on Dec. 16, 2013.
Last week the company released its third quarter financials which reported:
· Core funds from operations of $0.46 per share.
· Produced same-store net operating income growth of 1.5% over third quarter of 2012.
· Named Paul McDermott as the company’s new president and CEO.
· Net income of $5.8 million, or $0.09, compared to $9.6 million, or $0.14 per share in 2012.
The analysis on Washington reports that the company’s dividend yield is near a 5-year low, its revenue has been in decline over the past five years and its operating margin has also been in a long term decline.
Washington REIT has a market cap of $1.72 billion. Its shares are currently trading at around $25.91 with a P/E ratio of 79.70, a P/S ratio of 5.60 and a P/B ratio of 2.30. The company had an annual average earnings growth of 10.50% over the past ten years.
Dynavax Technologies Corp (DVAX)
Over the past week Dynavax Technologies’ price slipped to a record low and a result of this, there were three directors making buys back into the company. These insiders all made their buys at the share price of $1.08
Director Peggy Phillips purchased a total of 93,023 shares, costing her approximately $100,465 in this transaction. Since her buy the price per share has increased about 7.41%. Phillips now holds on to at least 138,023 shares of the company’s stock.
Arnold Oronsky made the largest buy of the week, adding 186,047 shares to his stake over the past few days. Oronsky spent a total of $200,931 on this transaction. Since his buy the price per share is up about 7.41%. Oronsky now owns over 375,000 shares of company stock.
Daniel Kisner purchased 10,000 sahres of Dynavax last week, costing him $10,800. Since his buy, the price per share has increased 7.41%. The director now holds on to 15,000 shares of his company’s stock.
It’s notable that these insider buys are the first insider transactions for the company in approximately a year.
Dynavax Technologies is a clinical-stage biopharmaceutical company. It discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
Dynavax’s historical revenue and net income:
These insider buys also come as the company’s public offering of common stock. Dynavax priced 79.57 million shares at the price of $1.075 per share. The offering closed on Oct. 30, 2013.
The company recently initiated its first human trial in its asthma project. The trial is under a collaborative agreement with AstraZeneca. Data from the trial is expected to be released mid-2014. The product being tested, AZD1419, was selected as a clinical candidate because of the extensive preclinical studies conducted by Dynavax and AstraZeneca.
Also over the past quarter Dynavax promoted their VP of Medical Affairs Robert Janssen, M.D. to the position of Chief Medical Officer and VP of Clinical Development.
The analysis on Dynavax Technologies reported that the company’s revenue has been in decline over the past five years, its operating margin is expanding and its price is near a 3-year low.
Dynavax Technologies has a market cap of $205.1 million. Its shares are currently trading at around $1.14 per share with a P/S ratio of 20 and a P/B ratio of 2.50.
You can view a complete list of CEO buys and sells here.
Try a free 7-day premium membership.